These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 29755356)

  • 1. Anti-Parkinson Potential of Silymarin: Mechanistic Insight and Therapeutic Standing.
    Ullah H; Khan H
    Front Pharmacol; 2018; 9():422. PubMed ID: 29755356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
    Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
    Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic Insights into the Pharmacological Significance of Silymarin.
    Wadhwa K; Pahwa R; Kumar M; Kumar S; Sharma PC; Singh G; Verma R; Mittal V; Singh I; Kaushik D; Jeandet P
    Molecules; 2022 Aug; 27(16):. PubMed ID: 36014565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight.
    Ranjan S; Gautam A
    Front Neurosci; 2023; 17():1159806. PubMed ID: 37274201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
    Albassam AA; Frye RF; Markowitz JS
    Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Unlocking the possibilities of therapeutic potential of silymarin and silibinin against neurodegenerative Diseases-A mechanistic overview.
    Ashique S; Mohanto S; Kumar N; Nag S; Mishra A; Biswas A; Rihan M; Srivastava S; Bhowmick M; Taghizadeh-Hesary F
    Eur J Pharmacol; 2024 Oct; 981():176906. PubMed ID: 39154829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroprotective effect of silymarin in a MPTP mouse model of Parkinson's disease.
    Pérez-H J; Carrillo-S C; García E; Ruiz-Mar G; Pérez-Tamayo R; Chavarría A
    Toxicology; 2014 May; 319():38-43. PubMed ID: 24607817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.
    Wen Z; Dumas TE; Schrieber SJ; Hawke RL; Fried MW; Smith PC
    Drug Metab Dispos; 2008 Jan; 36(1):65-72. PubMed ID: 17913795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Silymarin content in
    AbouZid SF; Chen SN; Pauli GF
    Ind Crops Prod; 2016 May; 83():729-737. PubMed ID: 27182123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective potential of silymarin against CNS disorders: insight into the pathways and molecular mechanisms of action.
    Borah A; Paul R; Choudhury S; Choudhury A; Bhuyan B; Das Talukdar A; Dutta Choudhury M; Mohanakumar KP
    CNS Neurosci Ther; 2013 Nov; 19(11):847-53. PubMed ID: 24118806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced production of silymarin by Ag+ elicitor in cell suspension cultures of Silybum marianum.
    Ashtiani SR; Hasanloo T; Bihamta MR
    Pharm Biol; 2010 Jun; 48(6):708-15. PubMed ID: 20645746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms.
    Haddadi R; Shahidi Z; Eyvari-Brooshghalan S
    Phytomedicine; 2020 Dec; 79():153320. PubMed ID: 32920285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interaction of isolated silymarin flavonolignans with iron and copper.
    Tvrdý V; Catapano MC; Rawlik T; Karlíčková J; Biedermann D; Křen V; Mladěnka P; Valentová K
    J Inorg Biochem; 2018 Dec; 189():115-123. PubMed ID: 30245273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of hepatoprotective flavonolignans from silymarin.
    Polyak SJ; Morishima C; Lohmann V; Pal S; Lee DY; Liu Y; Graf TN; Oberlies NH
    Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5995-9. PubMed ID: 20231449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A sensitive LC-MS/MS assay for the simultaneous analysis of the major active components of silymarin in human plasma.
    Brinda BJ; Zhu HJ; Markowitz JS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 902():1-9. PubMed ID: 22766231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Protective Activity of Silymarin and its Flavonolignans.
    Vostálová J; Tinková E; Biedermann D; Kosina P; Ulrichová J; Rajnochová Svobodová A
    Molecules; 2019 Mar; 24(6):. PubMed ID: 30875758
    [No Abstract]   [Full Text] [Related]  

  • 17. A Mini Review on the Chemistry and Neuroprotective Effects of Silymarin.
    Devi KP; Malar DS; Braidy N; Nabavi SM; Nabavi SF
    Curr Drug Targets; 2017; 18(13):1529-1536. PubMed ID: 28025940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.
    Bijak M
    Molecules; 2017 Nov; 22(11):. PubMed ID: 29125572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Human Sulfotransferases Active towards Silymarin Flavonolignans and Taxifolin.
    Vrba J; Papoušková B; Kosina P; Lněničková K; Valentová K; Ulrichová J
    Metabolites; 2020 Aug; 10(8):. PubMed ID: 32806559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.